The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.
The company’s oral PCSK9 inhibitor enlicitide was approved by FDA, a key pillar in the company’s cardiovascular pipeline renaissance.